NCT01800305View on ClinicalTrials.gov

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

PHASE1CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Healthy

Interventions

DRUG

Pegylated rhEPO

DRUG

EPIAO®

Trial Locations (1)

Unknown

302 Military Hospital of China, Beijing

All Listed Sponsors

lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY

NCT01800305 - PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual | Biotech Hunter | Biotech Hunter